Analysis of research on the benefits of clinical and economic effectiveness, safety of innovative drug cetuximab in the treatment of colorectal cancer
Journal Title: ScienceRise: Pharmaceutical Science - Year 2019, Vol 0, Issue 2
Abstract
<p><strong>The</strong><strong> </strong><strong>aim</strong> of the work is to analyze and systematize literature data on the benefits of clinical and economic efficiency, safety of cetuximab in the treatment of colorectal cancer.</p><p><strong>Materials and methods.</strong> Studies were conducted using databases on the Internet: PubMed; Food and Drug Administration, European Medicines Agency. It has used retrospective, logical, statistical and system-analytical research methods.<strong></strong></p><p><strong>Results.</strong> The analysis of clinical data suggests additional utility, high efficacy of cetuximab in the treatment of patients with metastatic colorectal cancer RAS wild type and expression of epidermal growth factor receptors EGFR compared to other drugs. Cetuximab exhibits a synergistic effect with a number of cytostatic drugs, and also increases the effect of radiotherapy, with no increased toxic reactions when co-administered. The administration of cetuximab in the treatment regimen increases the resectability of primary nonresectable metastases in the liver, as well as survival without progression in both operated patients and in inoperable cases. The drug is considered relatively safe. Skin rashes caused by cetuximab are associated with a significant improvement in overall survival, progression-free survival and overall response rates. The use of cetuximab in patients with colorectal cancer is accompanied by a lower economic burden on the budget of drug provision for cancer patients than bevacizumab. It should be noted that the development of cetuximab biosimilars will reduce the cost of treatment and improve access to colorectal cancer therapy.</p><p><strong>Conclusions.</strong> Thus, it has been shown that cetuximab is not only a clinically effective and relatively safe drug for the treatment of colorectal cancer, but also demonstrates its cost-effectiveness and additional benefits compared with other drugs, including bevacizumab</p>
Authors and Affiliations
Elena Litvinova
Keywords
Related Articles
- EP ID EP647862
- DOI 10.15587/2519-4852.2019.165681
- Views 146
- Downloads 0
Організація фармацевтичного забезпечення військовослужбовців, які брали участь у бойових діях, на засадах фармацевтичного права
<p>У статті наведено сучасний стан медико-фармацевтичного забезпечення пільгових категорій населення України, до яких чинним законодавством віднесено військовослужбовців, що брали участь у проведенні антитерористичної оп...
Study of medical kits from passenger trains
<p><strong>Aim </strong>of the article is to study the composition of the medical first aid kit, which should be equipped with trains.</p><p><strong>Materials and methods. </strong>The study used methods such as content...
Pharmacoeconomic analysis of the use of ramipril and candesartan in patients with arterial hypertension
<p>Arterial hypertension (AH) is the most common cardiovascular disease in the world and is the cause of disability of the population of the developed countries of the world. A feature of hypertension pharmacotherapy is...
Разработка технологии мягкой лекарственной формы на основе экстракта листьев лещины обыкновенной
<p>Сосудистые заболевания занимают существенное место в структуре заболеваемости населения Азербайджана. Среди них варикозная болезнь является самой распространенной патологией, которая поражает от 25 до 50% взрослого на...
Current state assessment of pharmaceutical care implementation in Ukraine
<p>At the modern stage of the pharmacy development, there were significant changes in the positioning of the pharmacist’s role in the health care system. It has contributed to the development of pharmaceutical care (PC)...